###### Strengths and limitations of this study

-   Understanding the mediating effects of symptoms within a cluster will explain how these are manifested in clinical practice.

-   The findings will have important clinical implications and could guide symptom cluster management strategies.

-   The study provided evidence that as part of a management strategy, by targeting fatigue, anxiety and depression may have a meaningful effect on pain.

-   Rigorous design and implementation allow for the generalisability of the findings in these group of patients.

-   The unavailability of longitudinal data limits the support of a definite model, which would demonstrate if the correlations between symptoms found in this study are stable over time.

Introduction {#s1}
============

Cancer treatments and cancer itself are a source of many symptoms and side effects[@R1] It is reported that on average patients with cancer experience 11--13 concurrent symptoms, while for patients with advanced disease the number can be even greater.[@R3] Often these symptoms are related to each other, called symptom clusters (SCs) or symptom constellations.[@R3] Dodd *et al* [@R4] defined symptom cluster as three concurrent and related symptoms that may or may not have a common aetiology. However, the authors suggested that a cluster can be composed of just two or more symptoms that form a stable group.[@R3] Symptoms can be related through a common mechanism or aetiology, by sharing common variance, or by producing different outcomes than individual symptoms.

The impact of these clusters can be accumulative and debilitating for the patient and far more serious and persistent than single symptoms. Their concurrent presence makes their clinical management complex and challenging. As a result, these clusters can affect the patient's overall health-related quality of life (HRQoL)[@R7] and significantly affect the patient's sense of well-being and his or her physical and social functions.[@R8]

A number of studies have tried to record the most common clusters in various cancer types,[@R4] however, due to the lack of agreement about a robust, clinically relevant definition of SCs, their results should be interpreted with caution. Although the groups of symptoms that tended to cluster were identified, there is limited consistency in the way in which these SCs and their associated variables were identified.[@R1]

Preceding studies, again by drawing on the weaknesses of the clinical definition of an SC, they provide limited information towards understanding the way (or ways) the symptoms are actually correlated to each other or to other variables (ie, HRQoL). Most of the models available adopt a serial mediation approach to the study of these clusters, suggesting a rather linear correlation between the symptoms.

According to the definition by Dodd *et al*,[@R4] for example, a cluster of pain, fatigue and insomnia is presented as a legitimate one. However, the authors supported that pain leads to fatigue and in turn insomnia and this is a rather linear representation. Therefore, the rationale for examining these symptom clusters within the mediational models is to explicate whether these symptoms can have an alternative way of interaction other than the one suggested in a linear way. What is further lacking in the current research is the role of other possible mediators such as cancer diagnoses which is also explored within this study.

These limitations are present with other SCs that have been identified so far in the literature leaving a gap to the best understanding of this phenomenon but most importantly to the way it can be best clinically managed. When interventions are directed to ameliorate a particular symptom within a cluster, other symptoms within the cluster may be relieved. However this evidence is not available to the best of our knowledge in the suggested mediational models available in the literature. As a result, current practice is driven based on a priori assumptions about the relationships among symptoms resulting in targeting the 'dominant' symptom. In the previous example, pain would have been identified as a 'dominant' symptom, and therefore, secondary attention is attributed to any other symptom that co-occurs.

These a priori assumptions are however not based on scientific evidence but rather have been established on clinical experience. However, a symptom cluster experienced by the patient creates a complex condition where pain is rarely reported as a single symptom, but as a distressing symptom is reported and addressed in a timely manner. However, the lack of knowledge in the ways symptoms might correlate to each other and with other variables, the question remains whether the dominant symptom in these situations is indeed pain. The question that also arises is whether there would be a clinical benefit if, for example, pain and fatigue are correlated and interventions were specifically designed to target both symptoms. The researchers so far had hypothesised that it is pain and this has become the common practice dominating the current clinical management of this specific SC. This study hypothesises that in the mediational models to be tested within this cluster of symptoms, fatigue, anxiety and depression will be identified as mediating factors in the pain-HRQoL linkage. Furthermore, the study hypothesises that the mediation role of anxiety, depression and fatigue will differ between the breast cancer and prostate cancer diagnoses.

Aim {#s1a}
---

The aim of this study was to provide evidence on the co-occurrence of and inter-relations between symptoms occurring as part of a cluster in two groups of patients diagnosed with breast and prostate cancer.

Methods {#s2}
=======

The data for the purpose of this paper came from a randomised control trial (NCT01275872) designed to test the effectiveness of guided imagery (GI) and progressive muscle relaxation (PMR) on a cluster of symptoms reported by patients diagnosed with breast or prostate cancer when receiving chemotherapy.[@R10] The patients in the study reported the following symptoms: fatigue, pain, nausea, vomiting and retching, anxiety and depression.

Measurements {#s2a}
------------

The data were collected through the use of appropriate valid and reliable measures. The pain intensity was assess through a 10-point Numeric Rating Scale (NRS) for pain where 0 indicated the absence of pain and 10 indicated the worst experienced level of pain. Within the cancer context, NRS used to assess the intensity of pain have a proven validity and reliability.[@R11]

The Cancer Fatigue Scale (CFS)[@R12] was used to assess the participants' levels of fatigue. The CFS consists of 3 dimensions with 15 items that assess patients' responses on physical, affective and cognitive aspects of their daily living. A 5-point Likert scale is used to assess each of the items where 1 denotes 'not at all' to 5 which denotes 'very much'. The possible scores range from 0 to 28 for the physical, 0 to 16 for the affective and 0 to 16 for the cognitive subscale. The CFS had good stability (average test--retest reliability r=0.69, p\<0.001) and good internal consistency (Cronbach's alpha coefficient for all 15 items=0.88).[@R13]

Nausea and vomiting were assessed through the Revised Rhodes Index of Nausea, Vomiting and Retching (INVR)[@R14] which consists of eight 5-point self-reported items designed to assess subjective and objective factors of nausea, vomiting and retching. The validity and reliability of the INVR in patients with cancer have been demonstrated in preceding studies.[@R15]

The levels of anxiety were assessed with the Zung Self-Rating Anxiety Scale which contains 20 items that assess physiological and psychological symptoms commonly associated with anxiety, and each item is answered on a 4-point Likert-type scale ranging from 'never' to 'always'.[@R16] Raw scores sum to 20--44 that signify normal anxiety levels, 45--59 signifying mild to moderate anxiety levels, 60--74 signifying moderate to severe anxiety levels and finally 75--80 indicating extreme anxiety levels. The scale's validity and reliability in cancer populations have been established in previous studies.[@R17]

The Beck Depression Inventory-II has been used to assess patients' level of depression according to 21 items that correspond to a specific symptom common among people with depression.[@R18] Each item is evaluated on a 4-point scale ranging from 0 to 3. The number of items' responses is summed to indicate the severity of depression as follows: 1--10 is considered normal, 11--16 indicated mild mood disturbance, 17--20 indicates borderline clinical depression, 21--30 represents moderate depression, 31--40 represents severe depression and over 40 indicates extreme depression. The Beck Depression Inventory has been extensively used in cancer populations where it demonstrated excellent validity and reliability.[@R19]

As with the majority of studies that explore symptom and symptom management, QoL is a frequently reported outcome that has been used to demonstrate the negative impact of symptoms but also to reflect on the effectiveness of symptom management strategies. HRQoL was included in the study due to the consistent evidence in the literature that the cluster of symptoms is associated to poor levels of QoL in patients diagnosed with cancer.[@R7] Therefore, HRQoL has also being introduced in this study as a variable that can be correlated to the studied symptoms. The HRQoL of the patients was assessed with the EORTC QLQ-C30- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire in addition to the module BR23 for patients with breast cancer and the module PR25 for patients with prostate cancer. The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain, nausea and vomiting), a global health status/QoL scale, and a number of single items assessing additional symptoms (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. The research items are assessed on a Likert scale ranging from 1 to 4 (1='not at all', 2='a little', 3='quite a bit', 4='very much'). Only the last two items assessing overall health and overall QoL are assessed on a scale ranging from 1 (very poor) to 7 (excellent).[@R22] The EORTC QLQ-C30 module has a proven record of excellent validity and reliability across different cancer populations and languages.[@R23]

The BR23 is a breast-specific module that comprises 23 questions to assess body image, sexual functioning, sexual enjoyment, future perspective, systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss. The questions of the module are assessed on a Likert scale ranging from 1 to 4 (1='not at all'; 2='a little'; 3='quite a bit'; 4='very much'). The validity and reliability of the BR23 module have been demonstrated in breast cancer populations.[@R24]

The PR 25 prostate-specific module consists of 25 items across 6 scales: urinary symptoms, incontinence aid, bowel symptoms, hormonal treatment-related symptoms, sexual active and sexual function. The module includes five conditional questions, conditioned on the need of incontinence aid and the status of being sexually active. The questions of the module are assessed on a Likert scale ranging from 1 to 4 (1='not at all'; 2='a little'; 3='quite a bit'; 4='very much'). The validity and reliability of the PR25 module have been extensively demonstrated in prostate cancer populations.[@R25]

Sample {#s2b}
------

As the rationale for this study was to test the correlations between symptoms identified as clusters, only the baseline (T0) measurements from both groups (intervention and control group) were included in the analysis. Based on predetermined criteria, 208 patients were included in the study. The sample included 104 female patients with breast cancer (52 in control group +52 in intervention group) and 104 patients with prostate cancer (52 in control +52 in intervention).

Statistical analysis {#s2c}
--------------------

Non-parametric bootstrapping analyses[@R26] were deployed to test the mediational model of anxiety, fatigue and depression as parallel mediators of the relationship between pain and HRQoL. The nausea, vomiting and retching were excluded from the analyses as these were not found to correlate with the other symptoms. In these analyses, mediation is significant if the 95% bias corrected and accelerated CIs (lower limit, LL), upper limit (UL) for the indirect effect (IE) do not include 0.[@R8] Moreover, separated regression analyses were deployed to explore the statistical association of cancer diagnosis and age of the patient with the HRQoL.

Three mediation models are hypothesised and explored. The first model is a cancer diagnosis adjusted parallel mediation model of IE of pain to HRQoL through anxiety, fatigue and depression. The second model is a moderated mediation model where the IEs of the mediating factors are explored on each cancer diagnosis (conditional IEs). The third model assumes a serial causal chain of the three mediators (serial mediation). Six different causal chains were explored in this model.

All involved variables in the analyses were standardised (z scores) before running the analyses, hence standardised coefficients are reported for the total, direct and IEs.

Analysis was performed by using the PROCESS function V.2.16.1 in SPSS V.21. The model 4 (model as a parameter in the PROCESS function) was used for the parallel mediation model, model 15 (moderated mediation) for the second mediation model and model 6 for the serial mediation models (SMMs).[@R27]

Model fit is also reported using the following: a χ^2^ (df, a Comparative Fit Index (CFI) \>0.90 and a root mean square error of approximation of \<0.10. The fit indices were derived using the package lavaan in R.[@R28]

A detail presentation of the study's methodology is presented elsewhere.[@R29]

Patient and public involvement statement {#s2d}
----------------------------------------

As part of the study, a group of patients with relevant diagnoses were consulted in identifying the study's research question and relevant hypotheses. The patients were not directly involved in the design of the study nor in the recruitment and carrying out of the study. The authors intend to disseminate results to study participants through written summaries; academic outputs will be publicised through traditional media channels and social media.

Results {#s3}
=======

Sample characteristics {#s3a}
----------------------

The sample consisted of 104 male (52 in the intervention group and 52 in the control group) and 104 female (52 in the intervention group and 52 in the control group) patients diagnosed with prostate and breast cancer. Eighty-six patients with prostate cancer were diagnosed with stage T3a, Gleason score 8 and the remaining 18 with stage T3b, Gleason score 9. Patients with breast cancer were all diagnosed with clinical stage T3N1M0. Most of the participants belong to the 41--50 and the 51--60 age groups (38.9% and 26.4%, respectively). Patients with prostate cancer were treated either with a combination of androgen deprivation therapy (ADT) and adjuvant chemotherapy or with a combination of ADT and radiation (65.3% and 19.2%, respectively).

The correlation analysis shows that HRQoL is negatively associated with pain (r=−0.462), fatigue (r=−0.601), anxiety (r=−0.595) and depression (r=−0.510) indicating that lower QoL is associated with higher levels of the psychological aspects as well as pain. Furthermore, pain is positively correlated with all psychological aspects and negatively correlated with HRQoL ([table 1](#T1){ref-type="table"}).

###### 

Pearson correlation coefficients between the variables

               Pain         Fatigue      Anxiety      Depression   HRQoL
  ------------ ------------ ------------ ------------ ------------ -------
  Pain         1                                                   
  Fatigue      0.567\*\*    1                                      
  Anxiety      0.590\*\*    0.715\*\*    1                         
  Depression   0.541\*\*    0.565\*\*    0.735\*\*    1            
  HRQoL        −0.462\*\*   −0.601\*\*   −0.595\*\*   −0.510\*\*   1

\*\*P\<0.001.

HRQoL, health-related quality of life.

Covariates {#s3b}
----------

Age was not found to be statistically associated with the level of HRQoL either on the total effects model (b=−1.13 p=0.27, predictors of HRQoL: pain, sex, age) or on the direct effect model (b=−0.9903 p=0.2866, predictors to HRQoL: anxiety, fatigue, depression, pain, gender, age).

Gender was found to be statistically associated with the HRQoL in the total effects model (b=−7.2972 p=0.0143) indicating that female patients experienced lower QoL compared with male patients. Therefore, gender, which in this study also reflects the type of cancer, is included in the mediation models as a statistical control variable.

Parallel mediation model {#s3c}
------------------------

Results based on 5000 bootstrapped samples indicated that, controlling for the gender, while the total effect of pain on HRQoL was significant (β~total~=−0.4616, SE=0.0612, p\<0.001), the direct effect was not (β~direct~=−0.0778, SE=0.0685, p=0.2576) and IEs are present ([figure 1](#F1){ref-type="fig"}).

![Parallel mediation model (n=208). Indirect effects of pain on Global HRQoL through anxiety, fatigue and depression. Model is controlled for the cancer diagnosis. Standardised effects are presented. The effects on the direct path from pain to global HRQoL depict the direct effect and the (total effect). \*P\<0.05, \*\*\*P\<0.001. HRQoL, health-related quality of life; QoL, quality of life.](bmjopen-2018-026809f01){#F1}

Overall, the three mediators fully mediate the relationship between pain and HRQoL (IE~overall~=−0.3839, 95% CI: LL=−0.5073 to UL=−0.2825) indicating that patients with increased pain are more likely to have higher levels of anxiety, fatigue and depression. Patients through the experience of high levels of anxiety, fatigue and depression are more likely to report lower levels of QoL.

Two out of the three mediators were found to significantly contribute to the overall IE. Specifically, there is as statistically significant IE of pain to HRQoL though anxiety (IE~anxiety~=−0.1378, 95% CI: LL=−0.2615 to UL=−0.0395), such that participants who indicated high levels of pain were more likely to feel anxiety, and through high levels of anxiety, more likely to report lower levels of HRQoL. In addition, there is as statistically significant IE of pain to HRQoL though fatigue (IE~fatigue~=−0.1856, 95% CI: LL=−0.2716 to UL=−0.1093), such that patients who indicated high levels of pain were more likely to feel fatigue, and through high levels of fatigue, more likely to report reduced HRQoL. Depression does not mediate the relationship between pain and HRQoL (IE~depression~=−0.0605, 95% CI: LL=−0.1575 to UL=0.0289).

Specific IE contrasts between the proposed mediators do not show statistically significant difference between the IEs of anxiety and fatigue (b=0.0478, 95% CI: LL=−0.260 to UL=0.0822). The ratio of the overall IE to the total effect is 0.8315 (95% CI: LL=0.5683 to UL=1.1718), while the ratio of the anxiety and fatigue IEs to the total effect is 0.2985 (95% CI: LL=0.0758 to UL=0.5711) and 0.4020 (LL=0.2230, UL=0.6317), respectively.

Moderated mediation model: cancer diagnosis moderation {#s3d}
------------------------------------------------------

The current analysis tests whether the IE of pain to HRQoL through anxiety or fatigue is moderated by cancer diagnosis, that is, whether the mediation effect observed earlier is statistically significantly different in patients with prostate and breast cancer.

A moderated mediation model is explored where anxiety and fatigue act as parallel mediators and diagnosis as a moderator ([figure 2](#F2){ref-type="fig"}) to the mediation. The proposed model is under model 15 of the PROCESS documentation[@R27] where the moderation effect takes place at the B-path (mediator to dependent) and at the C-path (direct path: independent to dependent). Model 15 (moderation effect not included to the A-path), was chosen over model 59 (moderation effect on all paths) since separate regression analysis for the interaction of diagnosis to the relationship of the independent (pain) to the mediators (anxiety and fatigue) did not reach statistical significance. The slope of the line relating the IE to the moderator is the 'Index of Moderated Mediation' (IMM).[@R28] The statistical significance of the IMM effect is assessed along with the conditional IEs across each cancer diagnosis.

![Moderated mediation model (n=208). Conditional indirect effects on cancer diagnosis (breast cancer coded as 1 and prostate cancer as 0) of pain on global HRQoL through depression. Note: Standardised effects are presented. The effects on the direct path from pain to global HRQoL depict the conditional direct effects for each cancer diagnosis as well as the unconditional direct effect C' path (total effect C-path). The effects of the moderator diagnosis to the paths represent the interaction slopes. Effects on the B-paths from the mediators to HRQoL represent the simple slopes. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001. HRQoL, health-related quality of life; QoL, quality of life.](bmjopen-2018-026809f02){#F2}

Diagnosis significantly moderated the mediational effect of fatigue (IMM=−0.2867 SE=0.1526, LL=−0.6127, UL=−0.0226) but did not moderate mediational effect of anxiety (IMM=−0.0709, SE=0.1414, LL=−0.3459, UL=+0.2089). This means that there is a meaningful difference in the magnitude of the conditional IEs of each cancer diagnosis in the mediation effect of pain to HRQoL through anxiety. Specifically, we observe that, for patients with prostate cancer, the conditional IE is trivial and not statistically significant (β=0.0746, SE=0.1474, LL=−0.1893, UL=+0.3853) but for patients with breast cancer, the conditional IE is stronger than prostate cancers' and statistically significant (β=−0.2121, SE=0.0434, LL=−0.307, UL=−0.1351) ([table 2](#T2){ref-type="table"}). Fatigue is a significant mediator to the relationship between pain and HRQoL in patients with breast cancer rather than patients with prostate cancer. There is no meaningful difference in the mediating effect of anxiety for the relationship between pain and HRQoL between prostate and breast cancer diagnoses.

###### 

Conditional indirect effect(s) of pain on HRQoL at gender and Index of Moderated Mediation

  Mediators   Moderator (gender)   β (SE)               95% CI
  ----------- -------------------- -------------------- ---------------------
  Anxiety                                               
              Male                 0.1324 (0.1314)      (−0.4076 to 0.1138)
              Female               −0.2033 (0.0578)\*   (−0.3315 to 0.1026)
  Fatigue                                               
              Male                 0.0746 (0.1463)      (−0.2015 to 0.3574)
              Female               −0.2121 (0.0436)\*   (−0.3034 to 0.1282)

  Moderated Mediation Index                                               
  --------------------------- ------------------- ----------------------- --
  Anxiety                     −0.0709 (0.143)     (−0.3583 to 0.2094)     
  Fatigue                     −0.2867 (0.156)\*   (−0.5996 to --0.0057)   

Bias-corrected bootstrapped CIs, 5000 bootstrap samples. Statistically significant moderated mediation occurs only for fatigue. Although there is a significant conditional indirect effect for females through the mediator anxiety, the difference between the conditional indirect effect for males is not significantly different than that of the females.

\*P\<0.05.

Serial mediation model {#s3e}
----------------------

Serial mediation hypothesises a causal chain linking of the mediators (anxiety, fatigue, depression), with a specified direction flow. For example, pain could increase anxiety, which in turn increases depression which could in turn increase fatigue and thus decrease QoL (ie, Pain-\>Anxiety-\>Depression-Fatigue-\>HRQoL).

The results show that the three mediators in a serial causal order (any order that is) fully mediate the relationship between pain and HRQoL (IE~overall~=−0.384, 95% CI: LL=−0.51 to UL=−0.284) and the ratio of the overall IE to the total effect is 0.8315 (95% CI: LL=0.5683 to UL=1.1718). The total IE and the ratio to the total effect, both are the same as in the parallel mediation model explored earlier.

Since three mediators were used, six different causal order models were produced ([table 3](#T3){ref-type="table"}). All six models were compared in terms of the significant path created by each different causal order of the mediators. SMM 1, SMM 2 and SMM 4 yielded only three significant indirect paths out of the seven possible paths, whereas SMM 3, SMM 5 and SMM 6 yielded 4, 5 and 6 significant paths, respectively.

###### 

Standardised indirect effects and ratio of indirect to total effects for the paths on the SMMs

                                             Indirect effects of pain on HRQoL   Ratio of indirect to total effect                   
  ------------------------------------------ ----------------------------------- ----------------------------------- --------------- -------------------
  SMM1: PN -\>AXT -\>DEP -\>FTG -\>HRQoL                                                                                             
   **PN -\>AXT -\>HRQoL**                    −0.138 (0.057)                      (−0.268 to --0.04)                  0.299 (0.126)   (0.082 to 0581)
   PN -\>AXT -\>DEP -\>HRQoL                 −0.042 (0.033)                      (−0.109 to 0.022)                   0.091 (0.074)   (−0.049 to 0.239)
   **PN -\>AXT -\>FTG -\>HRQoL**             −0.108 (0.032)                      (−0.186 to --0.057)                 0.234 (0.077)   (0.114 to 0.424)
   PN -\>AXT -\>DEP -\>FTG -\>HRQoL          −0.004 (0.01)                       (−0.028 to 0.013)                   0.009 (0.022)   (−0.029 to 0.063)
   PN -\>DEP -\>HRQoL                        −0.018 (0.018)                      (−0.069 to 0.005)                   0.04 (0.04)     (−0.012 to 0.153)
   PN -\>DEP -\>FTG -\>HRQoL                 −0.002 (0.005)                      (−0.019 to 0.005)                   0.004 (0.011)   (−0.01 to 0.041)
   **PN -\>FTG -\>HRQoL**                    −0.071 (0.024)                      (−0.13 to --0.033)                  0.154 (0.056)   (0.07 to 0.296)
  SMM2: PN -\>FTG -\>AXT DEP -\>HRQoL                                                                                                
   **PN -\>FTG -\>HRQoL**                    −0.186 (0.042)                      (−0.272 to --0.11)                  0.299 (0.126)   (0.082 to 0.581)
   **PN -\>FTG -\>AXT -\>HRQoL**             −0.074 (0.032)                      (−0.146 to --0.023)                 0.244 (0.077)   (0.119 to 0.427)
   PN -\>FTG -\>DEP -\>HRQoL                 −0.002 (0.006)                      (−0.022 to 0.006)                   0.088 (0.074)   (−0.047 to 0.241)
   PN -\>FTG -\>AXT -\>DEP -\>HRQoL          −0.022 (0.018)                      (−0.063 to 0.011)                   0.003 (0.008)   (−0.007 to 0.029)
   **PN -\>AXT -\>HRQoL**                    −0.064 (0.03)                       (−0.141 to --0.018)                 0.158 (0.058)   (0.071 to 0.304)
   PN -\>AXT -\>DEP -\>HRQoL                 −0.019 (0.017)                      (−0.062 to 0.008)                   0.002 (0.005)   (−0.004 to 0.024)
   PN -\>DEP -\>HRQoL                        −0.018 (0.017)                      (−0.067 to 0.005)                   0.038 (0.039)   (−0.012 to 0.147)
  SMM3: PN -\>DEP\> AXT -\>FTG-\>HRQoL                                                                                               
   PN -\>DEP -\>HRQoL                        −0.061 (0.048)                      (−0.156 to 0.03)                    0.131 (0.106)   (−0.072 to 0.343)
   **PN -\>DEP -\>AXT -\>HRQoL**             −0.074 (0.031)                      (−0.15 to --0.021)                  0.161 (0.07)    (0.044 to 0.324)
   PN -\>DEP -\>FTG -\>HRQoL                 −0.006 (0.015)                      (−0.043 to 0.018)                   0.014 (0.032)   (−0.038 to 0.094)
   **PN -\>DEP -\>AXT -\>FTG -\>HRQoL**      −0.058 (0.019)                      (−0.105 to --0.028)                 0.126 (0.047)   (0.057 to 0.248)
   **PN -\>AXT -\>HRQoL**                    −0.064 (0.029)                      (−0.138 to --0.019)                 0.138 (0.065)   (0.042 to 0.306)
   **PN -\>AXT -\>FTG -\>HRQoL**             −0.05 (0.017)                       (−0.094 to --0.025)                 0.108 (0.038)   (0.053 to 0.212)
   PN -\>FTG -\>HRQoL                        −0.071 (0.024)                      (−0.13 to --0.033)                  0.154 (0.056)   (0.07 to 0.296)
  SMM4: PN -\>AXT -\>FTG -\>DEP\> -\>HRQoL                                                                                           
   **PN -\>AXT -\>HRQoL**                    −0.138 (0.056)                      (−0.262 to --0,04)                  0.299 (0.125)   (0.076 to 0.578)
   **PN -\>AXT -\>FTG -\>HRQoL**             −0.113 (0.031)                      (−0.187 to --0061)                  0.244 (0.076)   (0.122 to 0.426)
   PN -\>AXT -\>DEP -\>HRQoL                 −0.041 (0.034)                      (−0.115 to 0.02)                    0.088 (0.075)   (−0.045 to 0.259)
   PN -\>AXT -\>FTG -\>DEP -\>HRQoL          −0.001 (0.004)                      (−0.013 to 0.003)                   0.003 (0.008)   (−0.007 to 0.028)
   **PN -\>FTG -\>HRQoL**                    −0.073 (0.025)                      (−0.131 to --0.031)                 0.158 (0.058)   (0.065 to 0.299)
   PN -\>FTG -\>DEP -\>HRQoL                 −0.001 (0.003)                      (−0.011 to 0.002)                   0.002 (0.006)   (−0.004 to 0.022)
   PN -\>DEP -\>HRQoL                        −0.018 (0.017)                      (−0.067 to 0.005)                   0.038 (0.039)   (−0.01 to 0.152)
  SMM5: PN -\>FTG -\>DEP\> AXT -\>HRQoL                                                                                              
   **PN -\>FTG -\>HRQoL**                    −0.186 (0.042)                      (−0.272 to --0.11)                  0.402 (0.103)   (0.223 to 0.632)
   PN -\>FTG -\>DEP -\>HRQoL                 −0.024 (0.019)                      (−0.064 to 0.011)                   0.052 (0.042)   (−0.023 to 0.146)
   **PN -\>FTG -\>AXT -\>HRQoL**             −0.052 (0.023)                      (−0.106 to --0.016)                 0.112 (0.051)   (0.031 to 0.23)
   **PN -\>FTG -\>DEP -\>AXT -\>HRQoL**      −0.022 (0.011)                      (−0.05 to --0.007)                  0.049 (0.024)   (0.015 to 0.11)
   PN -\>DEP -\>HRQoL                        −0.036 (0.031)                      (−0.106 to 0.016)                   0.079 (0.069)   (−0.034 to 0.238)
   **PN -\>DEP -\>AXT -\>HRQoL**             −0.034 (0.015)                      (−0.07 to --0.01)                   0.073 (0.034)   (0.021 to 0.156)
   **PN -\>AXT -\>HRQoL**                    −0.03 (0.019)                       (−0.082 to --0.004)                 0.065 (0.042)   (0.008 to 0.181)
  SMM6: PN -\>DEP\> FTG -\>AXT -\>HRQoL                                                                                              
   PN -\>DEP -\>HRQoL                        −0.061 (0.048)                      (−0.158 to 0.029)                   0.131 (0.107)   (−0.065 to 0.355)
   **PN -\>DEP -\>FTG -\>HRQoL**             −0.065 (0.023)                      (−0.12 to --0.03)                   0.14 (0.054)    (0.062 to 0.283)
   **PN -\>DEP -\>AXT -\>HRQoL**             −0.056 (0.023)                      (−0.111 to --0.017)                 0.122 (0.053)   (0.033 to 0.245)
   **PN -\>DEP -\>FTG -\>AXT -\>HRQoL**      −0.018 (0.009)                      (−0.043 to --0.006)                 0.039 (0.021)   (0.011 to 0.096)
   **PN -\>FTG -\>HRQoL**                    −0.121 (0.031)                      (−0.192 to --0.07)                  0.262 (0.073)   (0.146 to 0.44)
   **PN -\>FTG -\>AXT -\>HRQoL**             −0.034 (0.016)                      (−0.073 to --0.011)                 0.073 (0.035)   (0.021 to 0.16)
   **PN -\>AXT -\>HRQoL**                    −0.03 (0.019)                       (−0.082 to --0.004)                 0.065 (0.042)   (0.008 to 0.181)

Table shows standardised indirect effects with bootstrapped SEs; Paths in bold indicate statistically significant indirect effects.

Bias-corrected 95% CIs.

\*LL- Lower Limit, UL- Upper Limit

AXT, anxiety; DEP, depression; FTG, fatigue; HRQoL, health-related quality of life; PN, pain; SMM, serial mediation model.

SMM 3, SMM 5 and SMM 6 yielded a significant indirect path involving all three mediators in a causal chain. The path Pain-\>Depression-\>Anxiety-\>Fatigue-\>HRQoL in SMM 3 yielded the highest ratio of indirect to total effect; 0.126 (95% CI 0.056 to 0.248) among the three models ([table 3](#T3){ref-type="table"}).

The indirect paths involving fatigue and depression (one after the other and vice versa) were statistically significant in one out of the six SMMs and specifically in SMM6.

The indirect paths involving anxiety and depression (one after the other and vice versa) were statistically significant in three out of the six SMMs and specifically in SMM3, SMM5 and SMM6

The indirect paths involving fatigue and anxiety (one after the other and vice versa) were statistically significant in all SMMs. This result means that increased pain increases fatigue (or anxiety) which in turn increase anxiety (or fatigue) resulting in a decreased QoL. The serial causal effect of these two mediators was found significant in any casual order of the mediators in place.

[Figure 3](#F3){ref-type="fig"} depicts the effects of the direct paths linking pain to each mediator and among mediators resulting from the SMM 6 in which all the direct and IEs are statistically significant. The positive signs (+ve) of the effects are indicative of the increased anxiety, fatigue and depression that increased pain causes. Moreover, it shows that increased levels of each mediator is associated with a positive effect (ie, increase) in the levels of the mediator with a direct connection. All indirect paths from pain to HRQoL are negative, showing the reduction in HRQoL levels through the increase in the levels of the mediators. The SMM 6 results show that the worst the pain was the more it would contribute to depression, higher depression resulted to higher fatigue, higher fatigue led to higher levels of anxiety which in turn contributed to lower HRQoL.

![Serial mediation model 6 linking pain and quality of life (QoL) (n=212). Standardised effects are presented outside the parentheses with bootstrapped SEs in the parentheses. C'=direct effect of pain to HRQoL; C=total effect of pain to HRQoL; total indirect effect=−0.384, 95% biased corrected CI:−0.51 to --0.284; ratio of indirect to total effect: 0.832, 95% CI 0.58 to 1.17; model is controlled for cancer Diagnosis. Global fit indices: χ^2^=10.27(3), p=0.069, CFI=0.938, RMSEA=0.10 (0.04, 0.18). \*P\<0.05, \*\*\*P\<0.001. CFI, Comparative Fit Index; HRQoL, health-related quality of life; RMSEA, root mean square error of approximation.](bmjopen-2018-026809f03){#F3}

Discussion {#s4}
==========

The aim of this study was to explore the co-occurrence and inter-relations between symptoms that were reported by two groups of patients with cancer and HRQoL. With previous findings showing that these symptoms can be present in different clusters in these groups of patients,[@R30] we specifically aimed to demonstrate that pain, depression, fatigue, nausea, vomiting and retching and anxiety can form a common symptom cluster over the course of breast cancer and prostate cancer treatment. The findings showed that with the exception of nausea, vomiting and retching, the symptoms of pain, fatigue, anxiety and depression formed a common symptom cluster in patients with breast and prostate cancer. The findings also showed that HRQoL is negatively associated with pain, fatigue, anxiety and depression. This suggests that with these two groups of patients the symptoms consisting of the cluster need to be addressed collectively emphasising on pain management and focusing on depression, anxiety and fatigue. This provides a more comprehensive symptom management to the patient with also a positive effect on the HRQoL.

Parallel, serial and moderate mediation analyses yielded interesting results in relation to symptom correlations. Parallel mediation analysis showed that the three mediators (fatigue, anxiety and depression) fully mediate the relationship between pain and HRQoL. However, while anxiety and fatigue were found to significantly contribute to the overall IE, depression did not mediate the relationship between pain and HRQoL. The results demonstrated the mediating effect of these symptoms on pain and HRQoL, however, at the same time the results supported the notion that 'pain' needs to be targeted first. Although the data used for the analysis cannot support a definite model as these data were not longitudinal, however, it does suggest that researchers and clinicians should consider these alternative correlations between symptoms and HRQoL. For example, cancer diagnosis significantly moderated the mediational effect of fatigue but not anxiety. Therefore, for patients with prostate cancer conditional IE is minimal, but for patients with breast cancer, the effect is stronger and statistically significant. With the existence of many complex variable correlations being recorded in the literature in isolated symptom studies, these new findings suggest that conflicts in preceding studies may be resolved by the increased understanding of variable interaction in symptom clustering.

The exact underlying mechanisms by which symptoms correlate with each other are not to this date fully understood and this is an area that could contribute in the comprehensive management of symptom clusters through the development of effective multimodal interventions for patients with breast and prostate cancer for use in the active treatment phase. A variety of non-pharmacological interventions have been proposed for treating pain, fatigue, depression and anxiety including exercise, psychosocial, cognitive behavioural and nutritional.[@R32] However, most of these recommendations are proposed for use in single symptom management, perhaps with the exception of GI and PMR that its effectiveness was also tested in symptom cluster.[@R29] Further research is needed towards examining whether multimodal interventions can reduce pain and, in turn, reduce depression, fatigue and anxiety.

Clinical decision-making in symptom management is traditionally driven by the type of the symptom rather than its impact on the patient or its correlations to other symptoms that might simultaneously be present. Preceding studies[@R35] consistently showed that emphasis is given on pain management rather than management of other symptoms such as fatigue or anxiety within a clinical situation where a symptom cluster manifests. The main problem with these patterns in symptom management is that despite the knowledge that symptoms coexist; these are prioritised according to perceived importance. However, the correlation between the symptoms is purposively not taken into consideration including the likelihood that by treating, for example, fatigue in patients with breast cancer, the results of any pain management intervention might be fortified as well as the positive impact on HRQoL. On the same example, treating fatigue in patients with prostate cancer will most likely have no accumulating effect on the patient's responsiveness to pain management interventions. This example highlights that within the clinical setting such clinical decision-making has also an impact on the cost-effectiveness of the symptom management interventions, as resources can be purposively allocated to other symptoms or variables that mediate pain and HRQoL to maximise clinical management.

The study has some limitations. The main limitation is the small sample size; however, several statistically significant paths emerged and within-symptom paths were replicated across both study samples (ie, cancer type groups). The unavailability of longitudinal data limits the support of a definite model, which would demonstrate if the correlations between symptoms found in this study are stable over time. However, the fact that the patients in the study were all in the active treatment phase strengthens the generalisability of the results to patients with prostate and breast cancer during this phase.

The study demonstrated that pain, depression, fatigue, and anxiety tend to co-occur during the treatment phase, thus providing further evidence for this symptom cluster in two distinct samples of patients with breast and prostate cancer. The study also showed the direct and IEs of this symptom cluster on the person's HRQoL. Parallel mediation analysis showed that the three mediators (fatigue, anxiety and depression) fully mediate the relationship between pain and HRQoL. Similarly, in a serial causal order, the three mediators fully mediate the relationship between pain and HRQoL. The moderated mediation analysis showed that diagnosis significantly moderated the mediational effect of fatigue but did not moderate mediational effect of anxiety. There are explicit clinical implications of the study's findings that include assessment, prevention and intervention for anxiety, depression, fatigue and pain related to breast and prostate cancer treatment. This work provides preliminary evidence that targeting fatigue, anxiety and depression may have a meaningful effect on pain as a related symptom and potentially have a positive impact on HRQoL of patients with breast and prostate cancer.
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